Antibody CDMO Market Size To Reach $45.8 Billion By 2033

Antibody CDMO Market Growth & Trends

The global antibody CDMO market size is estimated to reach USD 45.8 billion by 2033, registering a CAGR of 9.38% from 2025 to 2033, according to a new report by Grand View Research, Inc. Increasing R&D activities pertaining to the discovery of novel antibody therapeutics, growing prevalence of cancer cases and rising collaborations amongst contract development & manufacturing organizations (CDMO) and biopharmaceutical companies are the key factors driving the growth of antibody CDMO market.

Antibodies are drug therapies, especially used in cancer treatment. These antibodies do not affect healthy cells in the body and improve the therapeutic index of the drug; these are two key reasons for the high demand for antibodies in the treatment of cancer. These factors have supported the development of antibody types such as Antibody-drug conjugates (ADCs) in clinical research.

Owing to the efficiency of antibodies in cancer treatment, biopharmaceutical companies are receiving a significant amount of funding for conducting antibody-related research. For instance, in October 2022, Mablink Bioscience raised USD 31 million from Series A funding to build its antibody ADC pipeline for cancer treatment. Similarly, in July 2021, ProfoundBio received USD 55 million from investors to accelerate the development of the antibody ADC pipeline. Hence, increasing efforts via biopharmaceutical companies to develop novel therapeutics pertaining to the treatment of cancer is one of the major factors supporting the market growth.

The COVID-19 pandemic had a considerable impact on the market. However, several players adopted in-organic strategic initiatives such as partnerships, mergers, and acquisitions to mitigate the impact of the pandemic and thereby witness a rebound in their sales revenue. Moreover, the geopolitical war between Ukraine and Russia has negatively impacted the antibody CDMO market, as clinical trials outsourced across the war-infected countries have been halted until further notice. This has greatly impacted certain countries, such as the U.S., due to which the overall global market has witnessed a moderate dip in its revenue during 2022.

 Request a free sample copy or view report summary: Antibody CDMO Market Report

Antibody CDMO Market Report Highlights

• Based on product, the monoclonal antibodies segment accounted for the largest share in 2022. The segment is driven by growing demand for anti-cancer-based monoclonal antibody treatment therapeutics, constituting a vast portion of the overall antibody therapeutics.

• Based on the source, the microbial segment dominated the market with the largest revenue share in 2024, driven by the growing importance of microbes in drug development, as this source uses microorganisms to produce enzymes, vaccines, antibiotics, and therapeutic proteins.

• Based on therapeutic area, the oncology segment accounted for the largest share in 2024, driven by the rising prevalence of cancer, advancing cancer therapeutics by providing specialized services for monoclonal antibodies, bispecific antibodies, and antibody-drug conjugates (ADCs).

• Based on end-use, the large pharma & biotech companies segment accounted for the largest share in 2024.

• North America antibody contract development & manufacturing organization market dominated the market in 2024 with a revenue share of 43.40%, attributed to strong biopharmaceutical innovation, advanced manufacturing infrastructure, and significant R&D investments.

Antibody CDMO Market Segmentation

Grand View Research has segmented the global antibody contract development & manufacturing organization market based on product, service, source, workflow, therapeutic area, end-use and region:

Antibody CDMO Product Outlook (Revenue, USD Million, 2021 - 2033)

• Monoclonal Antibodies (mAbs)

• Antibody-Drug Conjugates (ADCs)

• Bispecific/ Multispecific Antibodies

• Polyclonal Antibodies

• Others

Antibody CDMO Service Outlook (Revenue, USD Million, 2021 - 2033)

• Contract Development

  • Cell Line Development

  • Process Development

    • Upstream

    • Downstream

  • Analytical Testing & Method Validation

  • Scale-Up & Tech Transfer

• Contract Manufacturing

  • API Manufacturing

  • Finished Drug Products Manufacturing

• Packaging and Labelling

• Regulatory Affairs

• Logistics & Storage

• Others

Antibody CDMO Source Outlook (Revenue, USD Million, 2021 - 2033)

• Mammalian

• Microbial

Antibody CDMO Workflow Outlook (Revenue, USD Million, 2021 - 2033)

• Clinical

• Commercial

Antibody CDMO Therapeutic Area Outlook (Revenue, USD Million, 2021 - 2033)

• Oncology

• Infectious Diseases

• Neurological Disorders

• Cardiovascular Disease

• Metabolic Disorders

• Autoimmune Diseases

• Respiratory Diseases

• Ophthalmology

• Gastrointestinal Disorders

• Others

Antibody CDMO End-use Outlook (Revenue, USD Million, 2021 - 2033)

• Large Pharma & Biotech Companies

• Small & Mid-sized Pharma & Biotech Companies

• Others

Antibody CDMO Regional Outlook (Revenue, USD Million, 2021 - 2033)

• North America

  • U.S.

  • Canada

  • Mexico

• Europe

  • UK

  • Germany

  • France

  • Italy

  • Spain

  • Denmark

  • Sweden

  • Norway

• Asia Pacific

  • Japan

  • China

  • India

  • Australia

  • Thailand

  • South Korea

• Latin America

  • Brazil

  • Argentina

• Middle East & Africa

  • South Africa

  • UAE

  • Saudi Arabia

  • Kuwait

  • Qatar

  • Oman

List of Key Players in the Antibody CDMO Market

• Lonza Group

• Catalent, Inc

• Samsung Biologics

• WuXi Biologics

• AGC Biologics

• AbbVie Inc.

• Boehringer Ingelheim International GmbH

• Charles River Laboratories

• FUJIFILM Holdings Corporation

• mAbxience